Back to GSKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
6 competitors in Hepatitis B
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA10/23/2000
Infanrix Hexa
Infanrix hexa is indicated for primary and booster vaccination of infants from the age of 6 weeks and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. The use of Infanrix hexa should be in accordance with official recommendations.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Combined Hepatitis A and B vaccinePhase 3
Hepatitis B
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3
Infections, Meningococcal
62.5/25mcgPhase 3
Pulmonary Disease, Chronic Obstructive
FluoridePhase 3
Dental Caries
Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3
Haemophilus Influenzae Type b
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts